NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
+$0.05 today
- Market cap
- $283.19M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
Volume 0.31M
Average 0.18M
NPCE Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
NeuroPace, Inc.NASDAQ: NPCE
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$6.91M, compared with $13.59M a year earlier. Trailing-twelve-month net change in cash was -$12.24M.
Context
- Net change in cash amounted to 8.3% of revenue in FY2025, up 2.5 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near -$6.91M or moves back toward the trailing-twelve-month quarterly average of -$3.06M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 8.26M USD
- Year-over-year change
- +278.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.26M | +278.5% |
| FY2024 | 2024-12-31 | (4.63M) | -140.4% |
| FY2023 | 2023-12-31 | 11.45M | +191.0% |
| FY2022 | 2022-12-31 | (12.58M) | -69.0% |
| FY2021 | 2021-12-31 | (7.45M) | — |
Net Change in Cash vs competitors
How NPCE compares with its peers on the latest reported figures
- NPCE's LTM Mar 2026 net change in cash of $12.24M is the smallest of the 2 companies compared; the peer median is $30.37M.
- Its year-over-year change of -187.3% is the highest of 2, against a peer median of -234.6%.
- Net change in cash amounts to 12.3% of revenue for NPCE, versus a peer median of 51.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.37M | -234.6% | -5.6% | 51.4% | |
| LTM Mar 2026 | $12.24M | -187.3% | — | 12.3% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding NPCE) | $30.37M | -234.6% | -5.6% | 51.4% | |
Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Depreciation & Amortization | 296K | 2.99M | 1.61M | 1.77M | 1.95M |
| Deferred Income Tax | 5.48M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.29M | 8.35M | 9.56M | 10.28M | 11.09M |
| Change in Working Capital | 368K | (4.79M) | (2.48M) | (5.45M) | (4.01M) |
| Accounts Receivables | 1.3M | (391K) | (4.85M) | (537K) | (1.83M) |
| Inventory | (1.16M) | (2.13M) | (1.7M) | 251K | (3.67M) |
| Accounts Payables | 479K | 647K | 240K | 671K | (730K) |
| Other Working Capital | (259K) | (2.91M) | 3.82M | (5.84M) | 2.22M |
| Other Non-Cash Items | 1.07M | 3.67M | 4.58M | 2.59M | 1.43M |
| Operating Cash Flow | (24.58M) | (36.87M) | (19.7M) | (17.95M) | (11.01M) |
| Capital Expenditures | (384K) | (603K) | (173K) | (306K) | (332K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (85.01M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 24.4M | 23.2M | 9.3M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (85.4M) | 23.8M | 23.03M | 8.99M | (332K) |
| Debt Repayment | (4.09M) | 0 | 0 | 0 | (2.07M) |
| Common Stock Issued | 109.09M | 0 | 7.89M | 3.28M | 71.76M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (49.55M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.47M) | 490K | 239K | 1.05M | (543K) |
| Financing Cash Flow | 102.53M | 490K | 8.13M | 4.33M | 19.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (7.45M) | (12.58M) | 11.45M | (4.63M) | 8.26M |
| Free Cash Flow | (24.96M) | (37.47M) | (19.87M) | (18.26M) | (11.34M) |
NeuroPace, Inc.
NASDAQ:NPCE
Intrinsic Alpha fair value
Locked
Current Price
$8.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.